Vir Biotechnology (VIR)
(Real Time Quote from BATS)
$7.64 USD
-0.12 (-1.55%)
Updated Sep 23, 2024 12:52 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Vir Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 86 | 1,616 | 1,095 | 76 | 8 |
Cost Of Goods | 3 | 146 | 66 | 0 | 0 |
Gross Profit | 83 | 1,469 | 1,030 | 76 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 768 | 636 | 609 | 373 | 186 |
Income After Depreciation & Amortization | -684 | 833 | 421 | -297 | -178 |
Non-Operating Income | 56 | -79 | 129 | -2 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -628 | 754 | 550 | -299 | -175 |
Income Taxes | -13 | 238 | 21 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -615 | 516 | 529 | -299 | -175 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -615 | 516 | 529 | -299 | -175 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -674 | 831 | 426 | -289 | -174 |
Depreciation & Amortization (Cash Flow) | 11 | -2 | 6 | 8 | 4 |
Income After Depreciation & Amortization | -684 | 833 | 421 | -297 | -178 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 134.13 | 134.81 | 133.44 | 119.16 | 30.35 |
Diluted EPS Before Non-Recurring Items | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 |
Diluted Net EPS (GAAP) | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 |
Fiscal Year end for Vir Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.08 | 56.38 | 16.79 | 2.64 | 3.80 |
Cost Of Goods | 0.05 | 0.06 | 0.80 | 0.04 | 0.02 |
Gross Profit | 3.02 | 56.32 | 15.99 | 2.60 | 3.78 |
SG&A, R&D, and Dept/Amort Expenses | 161.65 | 136.40 | 155.01 | 189.33 | 218.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | -158.63 | -80.08 | -139.02 | -186.73 | -215.18 |
Non-Operating Income | 18.74 | 15.08 | 18.26 | 20.11 | 17.56 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -139.89 | -65.00 | -120.76 | -166.63 | -197.62 |
Income Taxes | -1.51 | 0.28 | -4.78 | -3.21 | -2.85 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -138.38 | -65.28 | -115.97 | -163.41 | -194.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -138.38 | -65.28 | -115.97 | -163.41 | -194.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 136.23 | 135.28 | 134.61 | 134.29 | 134.06 |
Diluted EPS Before Non-Recurring Items | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 |
Diluted Net EPS (GAAP) | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 |